NASDAQ:VIVO Meridian Bioscience - VIVO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $33.97 0.00 (0.00%) (As of 01/27/2023 04:19 PM ET) Add Compare Share Share Today's Range$33.96▼$33.9950-Day Range$31.15▼$33.9752-Week Range$19.97▼$34.38Volume1.17 million shsAverage Volume664,016 shsMarket Capitalization$1.49 billionP/E Ratio35.02Dividend YieldN/APrice Target$34.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Meridian Bioscience MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.1% Upside$34.00 Price TargetShort InterestBearish9.82% of Float Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews Sentiment1.21Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector947th out of 1,055 stocksDiagnostic Substances Industry13th out of 17 stocks 1.0 Analyst's Opinion Consensus RatingMeridian Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, Meridian Bioscience has a forecasted upside of 0.1% from its current price of $33.97.Amount of Analyst CoverageMeridian Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.82% of the float of Meridian Bioscience has been sold short.Short Interest Ratio / Days to CoverMeridian Bioscience has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Meridian Bioscience has recently increased by 11.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMeridian Bioscience does not currently pay a dividend.Dividend GrowthMeridian Bioscience does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMeridian Bioscience has received a 69.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Diagnostic test kits", and "Biochemical assay kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Meridian Bioscience is -1.21. Previous Next 2.9 News and Social Media Coverage News SentimentMeridian Bioscience has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Meridian Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VIVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Meridian Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Meridian Bioscience is held by insiders.Percentage Held by Institutions89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.54.Price to Book Value per Share RatioMeridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Meridian Bioscience (NASDAQ:VIVO) StockMeridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, isothermal reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.Read More Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comMeridian Bioscience (NASDAQ:VIVO) Sees Large Volume IncreaseDecember 29, 2022 | benzinga.comMeridian Bioscience's Return On Capital Employed OverviewJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 13, 2022 | seekingalpha.comMeridian Biosciences: Why I Moved On But May Go Back InDecember 12, 2022 | finance.yahoo.comMeridian Bioscience Announces Anticipated Closing Date of the Pending MergerDecember 12, 2022 | finance.yahoo.comMeridian Bioscience sets closing date for $1.53 billion dealNovember 22, 2022 | seekingalpha.comMeridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67MNovember 22, 2022 | finance.yahoo.comMeridian Bioscience (VIVO) Q4 Earnings Surpass EstimatesJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 17, 2022 | finance.yahoo.comBellRing Brands (BRBR) Beats Q4 Earnings EstimatesOctober 15, 2022 | uk.finance.yahoo.comMeridian Bioscience, Inc. (VIVO)September 28, 2022 | msn.comVivo X Fold Plus launched: Check price, specifications and other detailsSeptember 20, 2022 | seekingalpha.comVIVO Meridian Bioscience, Inc.September 15, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates VIVO, OCSL, AVLRSeptember 14, 2022 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVO, SAVE, AAWW, MNRLSeptember 12, 2022 | finance.yahoo.comHere's when Meridian Bioscience investors will vote on firm's $1.53B acquisitionSeptember 3, 2022 | reuters.comMeridian Bioscience IncAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCNAugust 5, 2022 | finance.yahoo.comMeridian Bioscience (VIVO) Meets Q3 Earnings EstimatesAugust 5, 2022 | finance.yahoo.comMERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTSJuly 29, 2022 | nasdaq.comMeridian Obtains Re-Authorization From FDA For Revogene SARS-CoV-2 Molecular AssayJuly 29, 2022 | nasdaq.comMeridian Bioscience Gets FDA Re-authorization Of EUA For Revogene SARS-CoV-2 Molecular AssayJuly 29, 2022 | morningstar.comSHAREHOLDER ALERT: Weiss Law Reminds VIVO, NFLX, VMW, and CMAX Shareholders About Its Ongoing InvestigationsJuly 27, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSBJuly 26, 2022 | seekingalpha.comMeridian Bioscience: High-Probability Merger ArbitrageJuly 13, 2022 | finance.yahoo.comRoyce Invetsment Partners: Small-Cap Premier Quality Strategy-2Q22 Update and OutlookJuly 13, 2022 | apnews.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, VIVO, EPZMSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Company Calendar Last Earnings11/22/2022Today1/27/2023Next Earnings (Estimated)2/03/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:VIVO CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Price Target and Rating Average Stock Price Forecast$34.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.47 Cash Flow$1.78 per share Price / Cash Flow19.12 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares43,828,000Free Float42,820,000Market Cap$1.49 billion OptionableOptionable Beta0.26 Social Links Key ExecutivesMr. John P. Kenny (Age 54)Pres, CEO & Director Comp: $1.51MDr. Lourdes G. Weltzien Ph.D. (Age 58)Exec. VP of Life Science Bus. Unit Comp: $665.66kMr. Tony Serafini-Lamanna (Age 60)Exec. VP of Diagnostics Comp: $600.53kMr. Andrew S. Kitzmiller (Age 43)Exec. VP & CFO Ms. Julie SmithSr. VP, Controller & Principal Accounting OfficerMr. Jeff PinkstonDirector of Corp. Fin.Mr. Charles WoodVP of Corp. Strategy, Bus. Devel. & Investor RelationsMr. Emerson C. Moser (Age 46)Sr. VP & Gen. Counsel Ms. Melissa J. McCareyVP of Global HRMs. Susan D. Rolih (Age 74)Consultant More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELMyriad GeneticsNASDAQ:MYGNHeskaNASDAQ:HSKACelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInsiders & InstitutionsComerica BankSold 7,328 shares on 1/26/2023Ownership: 0.060%Strs OhioSold 2,300 shares on 1/26/2023Ownership: 0.055%Havens Advisors LLCSold 50,200 shares on 1/25/2023Ownership: 0.061%Exchange Traded Concepts LLCBought 732 shares on 1/18/2023Ownership: 0.128%Maryland State Retirement & Pension SystemBought 18,087 shares on 1/18/2023Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions VIVO Stock - Frequently Asked Questions Should I buy or sell Meridian Bioscience stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares. View VIVO analyst ratings or view top-rated stocks. What is Meridian Bioscience's stock price forecast for 2023? 2 Wall Street analysts have issued 12 month price targets for Meridian Bioscience's stock. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for VIVO or view top-rated stocks among Wall Street analysts. How have VIVO shares performed in 2023? Meridian Bioscience's stock was trading at $33.21 at the beginning of the year. Since then, VIVO stock has increased by 2.3% and is now trading at $33.97. View the best growth stocks for 2023 here. When is Meridian Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023. View our VIVO earnings forecast. How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings results on Tuesday, November, 22nd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.05. The company earned $65.68 million during the quarter, compared to analyst estimates of $67.45 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. What is Jack Kenny's approval rating as Meridian Bioscience's CEO? 7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA). What is Meridian Bioscience's stock symbol? Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO." Who are Meridian Bioscience's major shareholders? Meridian Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Syquant Capital Sas (0.31%), Exchange Traded Concepts LLC (0.13%), Yousif Capital Management LLC (0.07%), Havens Advisors LLC (0.06%), Comerica Bank (0.06%) and Strs Ohio (0.06%). Insiders that own company stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, Felicia Williams, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lourdes Weltzien. View institutional ownership trends. How do I buy shares of Meridian Bioscience? Shares of VIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Meridian Bioscience's stock price today? One share of VIVO stock can currently be purchased for approximately $33.97. How much money does Meridian Bioscience make? Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.49 billion and generates $333.02 million in revenue each year. The company earns $42.46 million in net income (profit) each year or $0.97 on an earnings per share basis. How many employees does Meridian Bioscience have? The company employs 702 workers across the globe. Does Meridian Bioscience have any subsidiaries? The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.Read More How can I contact Meridian Bioscience? Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762. This page (NASDAQ:VIVO) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.